Jazz 2025 JPM Presentation_FINAL.pdf

《Jazz 2025 JPM Presentation_FINAL.pdf》由會員分享，可在線閱讀，更多相關《Jazz 2025 JPM Presentation_FINAL.pdf（27頁珍藏版）》請在三個皮匠報告上搜索。

1、January 2025Innovating to Transform the Lives of Patients and Their Families43rd Annual J.P.Morgan Healthcare ConferenceJanuary 2025MarkellaEPIDIOLEX patient diagnosed with Dravet syndromeJanuary 2025Transforming Lives.Redefining Possibilities.2Caution Concerning Forward-Looking StatementsThis prese

2、ntation contains forward-looking statements and financial targets,including,but not limited to,statements related to:the Companys growth prospects and future financial and operating results,including the ability of the Companys portfolio to drive long-term shareholder value;expectations with respect

3、 to indication expansion opportunities;2024 total,neuroscience and oncology revenue guidance and the Companys expectations related thereto;the Companys ability to drive significant cash flow generation;the Companys commercial expectations,including with respect to revenue diversification and its exp

4、ectations for significant growth;the Companys expectations with respect to the commercial potential of its products and product candidates,including the blockbuster potential for Epidiolex,the peak potential of zanidatamab,growth opportunities for Rylaze,Epidiolex/Epidyolex,Xywav and Ziihera and Zep

5、zelcas potential approval as a first line therapy,and the potential regulatory paths related thereto;the value and growth potential of its products;the Companys net product sales and goals for net product sales from new and acquired products;the Companys views and expectations relating to its patent

6、 portfolio,including with respect to expected patent protection;planned or anticipated clinical trial events,including with respect to initiations,enrollment and data read-outs,and the anticipated timing thereof,and planned or anticipated regulatory submissions and filings and other regulatory matte

7、rs,including potential approvals,including the timing thereof;and other statements that are not historical facts.These forward-looking statements are based on the Companys current plans,objectives,estimates,expectations and intentions and inherently involve significant risks and uncertainties.Actual

8、 results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties,which include,without limitation,risks and uncertainties associated with:maintaining or increasing sales of and revenue from Xywav,Rylaze,Z

9、epzelca,Epidiolex/Epidyolex,Ziihera and other key marketed products;effectively launching and commercializing the Companys other products and product candidates;the successful completion of development and regulatory activities with respect to the Companys product candidates;obtaining and maintainin

10、g adequate coverage and reimbursement for the Companys products;the time-consuming and uncertain regulatory approval process,including the risk that the Companys current and/or planned regulatory submissions may not be submitted,accepted or approved by applicable regulatory authorities in a timely m

11、anner or at all;the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success,including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients such as those experienced,and expected to be experienc

12、ed,by the Company;regulatory initiatives and changes in tax laws;market volatility;protecting and enhancing the Companys intellectual property rights and the Companys commercial success being dependent upon its obtaining,maintaining and defending intellectual property protection for its products and

13、 product candidates;delays or problems in the supply or manufacture of the Companys products and product candidates;complying with applicable U.S.and non-U.S.regulatory requirements,including those governing the research,development,manufacturing and distribution of controlled substances;government

14、investigations,legal proceedings and other actions;identifying and consummating corporate development transactions,financing these transactions and successfully integrating acquired product candidates,products and businesses;the Companys ability to realize the anticipated benefits of its collaborati

15、ons and license agreements with third parties;the sufficiency of the Companys cash flows and capital resources;the Companys ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax,accounting and other provisions and estimates;the Companys ab

16、ility to meet its projected long-term goals and objectives,in the time periods that the Company anticipates,or at all,and the inherent uncertainty and significant judgments and assumptions underlying the Companys long-term goals and objectives;the completion of financial closing procedures,final aud

17、it adjustments and other developments that may arise that would cause the Companys expectations with respect to the Companys 2024 revenue guidance to differ,perhaps materially,from the financial results that will be reflected in the Companys audited consolidated financial statements for the fiscal y

18、ear ended December 31,2024;and other risks and uncertainties affecting the Company,including those described from time to time under the caption“Risk Factors”and elsewhere in the Companys Securities and Exchange Commission filings and reports,including the Companys Annual Report on Form 10-K for the

19、 year ended December 31,2023 as supplemented by the Companys Quarterly Report on Form 10-Q for the quarter ended September 30,2024,and its future filings and reports.Other risks and uncertainties of which the Company is not currently aware may also affect its forward-looking statements and may cause

20、 actual results and the timing of events to differ materially from those anticipated.The forward-looking statements made in this presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements,even if they are subsequently made available by the Company

21、 on its website or otherwise.The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results,new information,future events,changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements wer

22、e made.January 20253CarolineRylaze patient diagnosed with ALL/LBLOur PurposeWho We Areis to innovate to transform the lives of patients and their families.We are focused on developing life-changing medicines for people with serious diseases,often with limited or no therapeutic options,so they can li

23、ve their lives more fully.ALL/LBL=acute lymphoblastic leukemia/lymphoblastic lymphoma;IH=idiopathic hypersomnia.JennieXywav patient living with IHJanuary 2025Positioned to Drive Long-term Shareholder Value4COMMERCIALGrowth and diversified revenues expected to generate significant cash flowPIPELINEFi

24、nancial strength to transact and well-positioned to be partner of choiceCORPORATE DEVELOPMENTZanidatamab and Zepzelca indication expansion opportunities;additional pipeline programs under developmentOperational excellence and a disciplined,strategic approach to capital allocationJanuary 2025AG royal

25、ties=high-sodium oxybate authorized generic royalty revenues.1The company expects that for the year ended December 31,2024,reported total,neuroscience and oncology revenues will meet the guidance range provided on November 6,2024.Jazz Pharmaceuticals plc has not finalized its financial results for t

26、he year ended December 31,2024,and actual results may differ;2Chart based on revenue as reported in 3Q24.52021 Revenue$3.1 billion41%of revenues driven by Xyrem in 2021Oncology+Epidiolex+Other RevenuesXyrem Revenue+AG Royalty RevenueXywav Revenue2024 Guidance1$4.0-$4.1 billionXyrem&AG royaltiesGrowi

27、ng and Diversified Commercial Portfolio2018 Revenue$1.9 billion74%of revenues driven by Xyrem in 2018Launched/AcquiredProducts11%of revenues2 driven by Xyrem and AG royalties in 3Q24January 2025Strategic Transactions Driving Growth and Expanding Capabilities6Rapidly established as treatment of choic

28、e in 2L SCLC$1.1B1 in revenue since launch in mid-2020Positive Phase 3 results from IMforte trial;Plan to submit sNDA for 1L ES-SCLC in 1H25Durable and long-lived asset in Epidiolex$2.7 billion2 in revenue since acquisition mid-2021Epidiolex poised to reach blockbuster status in 2025Expanded operati

29、onal footprint and in-house R&D capabilitiesSignificant regulatory progress with extensive development program ongoingPath to approval in 1L GEA with anticipated sBLA submission in 2025$2B+peak sales potentialFINANCIAL STRENGTH$2.6B in cash,cash equivalents and investments3$1.0B cash from operations

30、4$885M undrawn revolving credit facility5 PARTNER OF CHOICEDemonstrated global commercial footprint and capabilitiesA leader in neuroscienceRapidly growing oncology businessIn-house development expertiseTrack record of maximizing asset potentialZEPZELCARapidly Accretive TransactionGW ACQUISITIONTran

31、sformational TransactionZANIDATAMABBroad Oncology Development Transaction201920212022WELL-POSITIONED FORCORPORATE DEVELOPMENT1L/2L=first-and second-line;ES=extensive stage;GEA=gastroesophageal adenocarcinoma;R&D=research and development;sBLA=supplemental biologics license application;SCLC=small cell

32、 lung cancer;sNDA=supplemental new drug application.1Net product sales from launch in July 2020 to September 30,2024;2Net product sales from May 2021 to September 30,2024;3As of September 30,2024;4For the nine months ended September 30,2024;5As of December 31,2024.January 2025Expect to meet 2024 tot

33、al,neuroscience and oncology revenue guidance120 Consecutive YearsYoY Revenue Growth2005 2024G 13.5%Total Revenue CAGR2018 2024G midpoint27Track Record of Successfully Growing and Diversifying Commercial Portfolio2024G=2024 financial guidance as provided by Jazz Pharmaceuticals plc on November 6,202

34、4;CAGR=compound annual growth rate;YoY=year-over-year.1The company expects that,for the year ended December 31,2024,reported total,neuroscience and oncology revenues will meet the guidance range provided on November 6,2024.Jazz Pharmaceuticals plc has not finalized its financial results for the year

35、 ended December 31,2024,and actual results may differ;2Based on mid-point of guidance provided by Jazz Pharmaceuticals plc on November 6,2024;3Neuroscience revenues include high-sodium oxybate authorized generic royalties.2018201920202021202220232024GOncologyNeuroscience3$2.2B$2.4B$3.1B$3.7B$3.8B$4.

36、0B-$4.1B$1.9BJanuary 20258Focused Investments in Promising R&D PortfolioPipelineJanuary 2025Key Clinical ProgramsPHASE 1PHASE 2PHASE 3PHASE 4/REGULATORYNEAR-TERM CATALYSTSZanidatamabZiihera approved in 2L BTC in 4Q24Phase 3 top-line PFS readout estimated 2Q25Phase 3 confirmatory trial in 1L BTC ongo

37、ingPhase 3 EmpowHER-BC-303 trial now enrollingPhase 2 DiscovHER-Pan-206 trial initiatedZepzelcaPositive OS and PFS data:expect sNDA filing in 1H25JZP815JZP898EpidyolexKey Pipeline Programs1L/2L=first-and second-line;BC=breast cancer;BTC=biliary tract cancer;DS=Dravet syndrome;ES=extensive-stage;GEA=

38、gastroesophageal adenocarcinoma;HER2+=human epidermal growth factor receptor 2 positive;LGS=Lennox-Gastaut syndrome;OS=overall survival;PFS=progression-free survival;SCLC=small cell lung cancer;sNDA=supplemental new drug application;T-DXd=trastuzumab deruxtecan;TSC=tuberous sclerosis complex.1L ES-S

39、CLC combo with TecentriqPhase 3 1L BTC2L BTC(pivotal)Phase 3 2L SCLC confirmatory trialPhase 4 2L SCLC observational trial9I-SPY2 Trial:neoadjuvant treatment of locally advanced BCRAF&RAS mutant tumorsSolid tumorsPhase 3 1L GEA(pivotal)Phase 3 BC in patients who have progressed on previous T-DXd tre

40、atmentPhase 2 pan-tumor trial in HER2+solid tumorsJapan(LGS/TSC/DS)January 2025Zanidatamab Has the Potential to Transform HER2-Targeted Therapies10Best-in-Class Profile Addresses Unmet NeedNovel and Differentiated MOACompelling Clinical Data in Multiple Indications$2B+Commercial OpportunityZanidatam

41、ab is a highly active,differentiated HER2-targeted bispecific mAb with compelling and durable survival dataHER2=human epidermal growth factor receptor 2;mAb=monoclonal antibody;MOA=mechanism of action.January 2025Rapidly Advancing Zanidatamab Development Program1L/2L=first-and second-line;BC=breast

42、cancer;BTC=biliary tract cancer;EMA=European Medicines Agency;EU=European Union;GEA=gastroesophageal adenocarcinoma;HER2=human epidermal growth factor receptor 2;MAA=marketing authorization application;sBLA=supplemental biologics license application.202520242026 and BeyondBTCExpect to complete 1L co

43、nfirmatory trialGEAPotential 1L approval and launchExpanded market strategy BCOngoing execution of EmpowHER-BC-303 trialPan TumorOngoing execution of DiscovHER-Pan-206 trialBTC Ziihera approved in 2L BTC in 4Q24 Initiated 1L confirmatory trial 2L BTC MAA validated by EMA GEA Enrollment on track for

44、Phase 3 HERIZON-GEA-01 trialBC Phase 3 EmpowHER-BC-303 trial initiatedPan Tumor Phase 2 DiscovHER-Pan-206 trial initiatedBTCPotential EU approval as early as 2Q25GEAHERIZON-GEA-01 top-line results estimated 2Q25Expect to submit sBLA in 1LPotential further development in neoadjuvant/adjuvant GEA popu

45、lation 11Goal:become the HER2-targeted therapy of choiceJanuary 2025Zepzelca:Positive Top-Line Results from 1L ES-SCLC Phase 3 TrialDiagnosed1L Treatment2L Treatment30K27K17K9K21K8K19KLS SCLCES SCLC2L+SCLC1L/2L=first-and second-line;ES=extensive stage;LS=limited stage;OS=overall survival;PFS=progres

46、sion-free survival;SCLC=small cell lung cancer;sNDA=supplemental New Drug Application.1Approximate U.S.SCLC patient numbers,sources:SEER Cancer Stat Facts https:/seer.cancer.gov/statfacts/html/lungb.html,accessed April 19,2019;American Cancer Society,https:/www.cancer.org/cancer/small-cell-lung-canc

47、er/about/what-is-small-cell-lung-cancer.html,accessed April 12,2019;Kantar Health Treatment Architecture SCLC July 2018;Jazz primary market research May 2019;2Paz-Ares,L.et al.Durvalumab,with or without tremelimumab,plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung c

48、ancer:3-year overall survival update from CASPIAN.ESMO Open.2022 Apr;7(2):100408.SCLC U.S.Patients1 IMforte Phase 3 Trial:Demonstrated statistically significant and clinically meaningful improvement in OS and PFS primary endpoints for 1L ES-SCLC Potential to delay disease progression and extend surv

49、ival for patients Plan to submit sNDA for 1L ES-SCLC indication in 1H25Significant unmet need:Expected median OS for 1L ES-SCLC patients is 13 months2 In the U.S.,there are 30,000 1L SCLC patients,with 27,000 currently treated in 1L and 17,000 treated in 2L1 70%of 1L patients have extensive stage SC

50、LC112January 202513Key Commercial ProductsHighly Differentiated Therapies Poised for GrowthJanuary 202514Highly Differentiated Medicines for Patients with Serious Diseases1L/2L=first-and second-line;ALL/LBL=acute lymphoblastic leukemia/lymphoblastic lymphoma;ES-SCLC=extensive-stage small cell lung c

51、ancer;HER2+=human epidermal growth factor receptor 2+;HSR=hypersensitivity;IH=idiopathic hypersomnia.1Based on 3Q24 revenues.Diverse product mix+strong cash flow generationNeuroscienceOncology#1 branded treatment for narcolepsy and only approved IH therapy#1 branded treatment for epilepsyStandard of

52、 care in pediatric ALL/LBL patients with asparaginase HSR reaction#1 treatment in 2L ES-SCLC;expansion opportunity in 1L ES-SCLCPotential to be the therapy of choice in multiple HER2+tumorsTop-line growth driven by diversified businesses spanning Sleep,Epilepsy and Oncology,each annualizing$1B1Janua

53、ry 2025Ziihera:Unique MOA Drives Compelling Clinical Profile and Patient Outcomes15Favorable tolerability profile contributes to improved patient quality of lifeCompelling and durable responses help drive improved patient outcomes in HER2+patientsUnique dual-targeting HER2 bispecific antibody provid

54、es differentiated treatmentHER2=human epidermal growth factor receptor 2;MOA=mechanism of action.Combination data supports ability to combine with other agents in multiple HER2+indicationsJanuary 202551.6%OverallResponse Rate114.9mMedian Durationof Response12.5%DiscontinuationRate1MarkZiihera patien

55、t living with Biliary Tract CancerZiihera Clinical DataBTC Launch:Building Momentum for Multiple Indications2L=second line;ASCO=American Society of Clinical Oncology;BTC=biliary tract cancer;HER2=human epidermal growth factor receptor 2;M=month.1Data as presented by Pant et al.at ASCO 2024.Launch ob

56、jectivesEstablish Ziihera as the standardof care for 2L HER2+BTCBuild momentum for Ziiheras potential as a transformative next-generation HER2-targeting agent16January 2025BTC Launch Driven by Proven Jazz Oncology Team and InfrastructureRight Team,Right Capabilities Proven team with deep oncology ex

57、perience,including extensive expertise in the HER2 therapy space will help drive additional adoption and uptake Infrastructure in place for a successful Ziihera launch Significant overlap in existing call universe covering key customers and accounts Leverage Jazzs established presence across sales,m

58、arketing,medical and accessKey Customer Focus Access,distribution,reimbursement,and patient support services ensure customers can readily order Ziihera,help patients navigate reimbursement approvals,and provide patient support through dedicated Jazz Resources and the JazzCares suite of servicesRobus

59、t Access and Patient Support Services17BTC=biliary tract cancer;HER2=human epidermal growth factor receptor 2.January 2025Zanidatamab:De-Risked Near-Term Opportunity with$2B+Peak PotentialInitiated U.S.launch activities in 2L BTC1L BTC confirmatory trial ongoingHERIZON-BTC-01:Updated data at ASCOExp

60、anded opportunity across lines of therapy1:Post T-DXd(Ph3 EmpowHER trial)Early lines of therapy(neoadjuvant)Novel combinationsInitiated Ph3 EmpowHER trial 2H24:Zanidatamab+chemo vs.tras+chemo in patients with HER2+BC whose disease has progressed on previous T-DXd treatmentPotential for novel chemo-f

61、ree regimen for HER2+/HR+patients1Ongoing trials in early breast cancer:I-SPY2 Trial4MD Anderson collaborationSignificant regulatory progress:Ziihera now approved in the U.S.for the treatment of adults with previously treated,unresectable or metastatic HER2+(IHC3+)BTC EMA validated MAA;potential app

62、roval as early as 2Q25Biliary Tract CancerGastroesophageal AdenocarcinomaBreast CancerPath to approval in 1L GEA with sBLA submission HER2+/PD-L1 negative:opportunity to address unmet need and replace trastuzumab1HER2+/PD-L1 positive:opportunity to replace trastuzumab as HER2-targeted therapy of cho

63、ice1Opportunity to explore potential in neoadjuvant populations11L/2L=first-and second line;ASCO=American Society of Clinical Oncology;BC=breast cancer;BTC=biliary tract cancer;EMA=European Medicines Agency;GEA=gastroesophageal adenocarcinoma;HER2=human epidermal growth factor receptor 2;HR+=hormone

64、 receptor positive;IHC=immunohistochemistry;MAA=marketing authorization application;NSCLC=non-small cell lung cancer;PD-L1=programmed cell death ligand 1;sBLA=supplemental biologics license application;T-DXd=trastuzumab deruxtecan;tras=trastuzumab.1Pending regulatory approvals;2Incidence sources:Kan

65、tar reports,ToGA surveillance report;SEER,cancer.gov;ClearView Analysis;GLOBOCAN,Data on file;3Major markets,U.K,France,Germany,Spain,Italy;4NCT01042379,in collaboration with QuantumLeap Healthcare Collaborative;5Incidence source estimates derived from multiple sources:Decision Resources Group,Kanta

66、r Health,Jazz Market Research,data on file;6Funda Meric-Bernstam et al,Zanidatamab,a novel bispecific antibody,for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers:a phase 1,dose-escalation and expansion study,The Lancet Oncology,Volume 23,Issue 12,2022,Pages

67、 1558-1570,ISSN 1470-2045,https:/doi.org/10.1016/S1470-2045(22)00621-0.1812,000 BTC cases annually2 in U.S.,Europe3 and Japan150,000BC cases annually5 in U.S.,Europe3 and Japan63,000GEA cases annually2 in U.S.,Europe3 and JapanBroad PotentialBeyond BTC,GEA,and BCOther HER2-Expressing CancersBroad po

68、tential beyond BTC,GEA,and BC in multiple HER2-expressing indications based on compelling clinical activity from early trials6:Colorectal NSCLCOvarianEndometrialPancreaticBladderSalivary GlandAmpullaryOther HER2-expressing solid tumors Initiated Phase 2 DiscovHER-Pan-206 Zanidatamab monotherapy in p

69、reviously-treated patients with no available treatment optionsJanuary 2025Zepzelca:Opportunity to Redefine 1L SCLC Treatment Paradigm19Well-established as 2L SCLC treatment of choice$1.1 billion1 in revenue since launch in mid-2020Plan to submit sNDA for 1L ES-SCLC in 1H25 Reported statistically sig

70、nificant and clinically meaningful OS and PFS results from the Phase 3 trial in combination with Tecentriq(atezolizumab),conducted in collaboration with Roche2 Significant unmet need:expected median OS for ES 1L SCLC patients is 13 months3 Potential to increase duration of response with earlier line

71、 patients In the U.S.,there are 30,000 1L SCLC patients,with 27,000 currently treated in 1L and 17,000 treated in 2L41L/2L=first-and second-line;ES=extensive-stage;OS=overall survival;PFS=progression-free survival;SCLC=small cell lung cancer;sNDA=supplemental New Drug Application.1Net product sales

72、from launch in July 2020 to September 30,2024;2F.Hoffmann-La Roche Ltd.;3Paz-Ares,L.et al.Durvalumab,with or without tremelimumab,plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer:3-year overall survival update from CASPIAN.ESMO Open.2022 Apr;7(2):1004008;4App

73、roximate U.S.SCLC patient numbers,sources:SEER Cancer Stat Facts https:/seer.cancer.gov/statfacts/html/lungb.html,accessed April 19,2019,American Cancer Society,https:/www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html,accessed April 12,2019,Kantar Health Treatmen

74、t Architecture SCLC July 2018,Jazz primary market research May 2019.DonnaFormer Zepzelca patient living with SCLCJanuary 2025Rely on Rylaze:Critical Component of U.S.ALL/LBL Treatment Protocols20ALL/LBL=acute lymphoblastic leukemia/lymphoblastic lymphoma.1Salzer W,Bostrom B,Messinger Y,et al.Asparag

75、inase activity levels and monitoring in patients with acute lymphoblastic leukemia.Leuk Lymphoma.2018;59(8):1797-1806;2Global net product sales from launch in July 2021 to September 30,2024.Sustained asparaginase activity over the course of therapy essential to treatment success of ALL/LBL patients1

76、$1.1 billion2 in revenue since launch in mid-2021 Only therapy available to patients in the U.S.who have a hypersensitivity reaction to E.coli-derived asparaginaseContinued strong demand driven by:Increased use in adolescent/young adult setting Switching to Rylaze at first sign of hypersensitivity r

77、eaction and due to treatment-related issuesWillowRylaze patient diagnosed with ALLJanuary 2025Epidiolex:Durable Growth;High Unmet Need in Pediatric Onset EpilepsyBroad spectrum efficacy through novel mechanism of action Poised to reach blockbuster status in 2025 Continued education on synergies from

78、 treatment in combination with clobazam Further data generation,including beyond-seizure benefits from the EpiCom1 study in TSC and nurse-reported responses to the BECOME2,3 survey in long-term care facilities presented at AES 2024 Launched Nurse Navigator program to help patients and families addre

79、ss medication-related topics Additional opportunity to drive growth in adult patient setting21AES=American Epilepsy Society;LGS=Lennox-Gastaut syndrome;TSC=tuberous sclerosis complex.1Eeghen,AM,Thiele,EA,et al.Poster presented at:World Congress of Neurology,October 15-19,2023;2Salazar TD,Berg A,Dane

80、se SR,et al.Poster presented at:American Epilepsy Society Annual Meeting;December 3-7,2021;Chicago,IL;3Berg A,Perry MS,Salazar TD et al.Poster presented at:American Epilepsy Society Annual Meeting;December 3-7,2021;Chicago,IL.CoreyEpidiolex patient living with LGSJanuary 2025Xywav:Differentiated by

81、Low Sodium;IH Provides Growth Opportunity22FDA=Food and Drug Administration;IH=idiopathic hypersomnia.1Based net product sales reported for quarter ended September 30,2024.CindyXywav patient living with IH Annualizing over$1.5 billion1 as of 3Q24 Xywav remains#1 branded treatment for narcolepsy Xywa

82、v is the only approved oxybate therapy that doesnt carry a warning and precaution related to high sodium intake FDA published its summary of clinical superiority findings stating Xywav is clinically superior to Xyrem by means of greater safety Positive impact from Field Nurse Educator program suppor

83、ting both narcolepsy and IH See most opportunity for growth in IH as the only approved therapy to treat IH and no near-term competitionJanuary 202523Well-Positioned to Deliver Long-Term ValueOperational Excellence and Commercial ExecutionJanuary 2025Delivering Significant Value Through Strategic Cap

84、ital Allocation1For the nine months ended September 30,2024;2As of September 30,2024;3As of December 31,2024.STRONG FINANCIAL POSITIONDISCIPLINED CAPITAL DEPLOYMENTSTRATEGIC PRIORITIESCOMMERCIAL GROWTHNew indications Geographic expansionPIPELINE EXPANSIONAdvancing internal assetsLicensing new assets

85、OPERATIONAL EXCELLENCEDisciplined and strategic capital allocationMaximize value$885MUndrawn revolving credit facility3$1.0BCash from operations1Diversified and growing revenue base Differentiated pipeline to support future growthCorporate development contributes to growth and diversification$2.6BCa

86、sh,cash equivalents and investments2 24January 2025Well-Positioned to Deliver Meaningful Shareholder Value25COMMERCIAL EXECUTIONReaching blockbuster statusMeaningful growth opportunity in IHExecuting launch in 2L BTCTreatment of choice in 2L SCLCPIPELINE CATALYSTSPhase 3 1L GEA top-line data:estimat

87、ed 2Q25Potential EU 2L BTC approval as early as 2Q25Phase 3 EmpowHER late-line BC trial is enrollingExpect to submit sNDA for 1L ES-SCLC in 1H25ZanidatamabCORPORATE DEVELOPMENTContinued focus on diversifying transactions to drive long-term growth and valueNear universal adoption in U.S.pediatric pro

88、tocolsZepzelca1L/2L=first-and second-line;BC=breast cancer;BTC=biliary tract cancer;ES=extensive stage;EU=European Union;GEA=gastroesophageal adenocarcinoma;IH=idiopathic hypersomnia;SCLC=small-cell lung cancer;sNDA=supplemental new drug application.Operational excellence and a disciplined,strategic approach to capital allocationQ&AJanuary 202526Thank YouJanuary 202527